Crossmark

The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients

Crossref DOI link: https://doi.org/10.1186/s12967-019-1828-0

Published Online: 2019-03-08

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Dal Bello, M. G. https://orcid.org/0000-0002-4952-1873
Filiberti, R. A.

Alama, A.

Orengo, A. M.

Mussap, M.

Coco, S.

Vanni, I.

Boccardo, S.

Rijavec, E.

Genova, C.

Biello, F.

Barletta, G.

Rossi, G.

Tagliamento, M.

Maggioni, C.

Grossi, F.
License Information

Text and Data Mining valid from 2019-03-08
More Information

Article History

Received: 28 September 2018

Accepted: 1 March 2019

First Online: 8 March 2019